| EPC473 | Multiple strategies are needed for enrolling individuals in randomized COVID-19 trials. Lessons learned from a home base postexposure trial in Argentina | E-poster | COVID-19 prevention |
| EPC472 | Early receipt of COVID-19 vaccines among people living with HIV: age, knowledge, and trust as determinants | E-poster | COVID-19 prevention |
| EPC471 | Safety and immunogenicity of Sputnik-V, AstraZeneca and Sinopharm vaccines against SARS-CoV-2 in people living with HIV | E-poster | COVID-19 prevention |
| EPC470 | 'Why do you want to kill me again? Isn't HIV enough?' Acceptability and factors influencing uptake of COVID-19 vaccines among persons living with HIV in three districts in Uganda | E-poster | COVID-19 prevention |
| EPC469 | Anti-SARS-CoV-2 antibodies after vaccination in people living with and without HIV | E-poster | COVID-19 prevention |
| EPC468 | Nitazoxanide as post exposure prophylaxis (PEP) of COVID-19 household contacts (FH-53 PENTZ) | E-poster | COVID-19 prevention |
| EPC467 | Omicron: infection rate and clinical outcomes in Johannesburg, South Africa | E-poster | COVID-19 prevention |
| EPC466 | Coronavirus vaccine safety in people living with HIV/AIDS | E-poster | COVID-19 prevention |
| EPC465 | Lopinavir/Ritonavir post-exposure prophylaxis did not protect against Covid-19 | E-poster | COVID-19 prevention |
| EPC464 | SARS CoV-2 seroprevalence in a cohort of people living with HIV before COVID-19 vaccination, Rio de Janeiro, Brazil | E-poster | COVID-19 testing |